Mr. Graham Farrell reports
WAYLAND PROVIDES UPDATE ON GERMAN TENDER PROCESS
Wayland Group Corp. would like to address recent reports in the media about the selection process in Germany for domestic medical cannabis cultivation.
Earlier today, the German Federal Institute for Drugs and Medical Devices (BfArM) announced that nine of the 13 cultivation licences that were previously announced have been officially awarded. Wayland, through its joint venture with Demecan GmbH, was originally selected by BfArM to receive three licences to produce medical cannabis in Germany. Per the announcement, four licences remain under review, as they have been challenged by a third party.
Wayland's quality concept received 60 out of 60 points for quality and 40 out of 40 points for price. The company believes that its concept is clearly superior to that of the parties challenging the award to Demecan and does not believe there is merit to the complaints. Wayland fully expects that the award of three lots to Demecan will be confirmed.
More information will be provided once it becomes available.
About Wayland Group Corp.
Wayland Group is a vertically integrated cultivator and processor of cannabis. The company was founded in 2013 and is based in Burlington, Ont., Canada, and Munich, Germany, with production facilities in Langton, Ont., where it operates a cannabis cultivation, extraction, formulation and distribution business under federal licences from the government of Canada. The company also has production operations in Dresden, Saxony, Germany, Regensdorf, Switzerland, and Allesandria, Piedmont, Italy. Wayland Group will continue to pursue new opportunities globally, including the consummation of its previously announced transactions in the United Kingdom, Australia, Colombia and Argentina, in its effort to enhance lives through cannabis.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.